Health insurance companies often deny coverage for new medications that treat children and teens with obesity and type 2 diabetes, meaning many patients wh
Health insurance companies often deny coverage for new medications that treat children and teens with obesity and type 2 diabetes, meaning many patients who need treatment are unable to afford it, according to a study presented at ENDO 2024, the Endocrine Society s annual meeting in Boston, Mass.
BOSTON — From 2019 to 2023, insurance covered GLP-1 receptor agonist prescriptions at a Texas hospital for less than 70% of young people with type 2 diabetes and less than 40% of those with obesity.In addition, 44% of pediatric patients with obesity and 17% with type 2 diabetes prescribed liraglutide (Saxenda, Victoza; Novo Nordisk) discontinued the medication before reaching the approved